PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC

NCT05737563 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

380

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma Abdominal Stage 0

Interventions

DRUG: PD-1 Inhibitors
DRUG: Irinotecan
DRUG: Capecitabine tablets

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]